Patents by Inventor Stewart Abbot
Stewart Abbot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170240860Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: October 28, 2015Publication date: August 24, 2017Applicant: Anthrogenesis CorporationInventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
-
Publication number: 20170000828Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.Type: ApplicationFiled: September 22, 2016Publication date: January 5, 2017Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Publication number: 20160362659Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perforate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrate erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: December 22, 2015Publication date: December 15, 2016Applicant: Anthrogenesis CorporationInventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Publication number: 20160361366Abstract: Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.Type: ApplicationFiled: October 22, 2015Publication date: December 15, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Aleksandr Kaplunovsky, Vladimir Jankovic, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang
-
Publication number: 20160137980Abstract: Provided herein are methods in the field of cell culture, specifically of culture and expansion of immune cells, e.g., T lymphocytes.Type: ApplicationFiled: June 23, 2014Publication date: May 19, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, Willard Foss, Thomas Daniel
-
Publication number: 20160106784Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.Type: ApplicationFiled: December 22, 2015Publication date: April 21, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
-
Patent number: 9254302Abstract: Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells.Type: GrantFiled: April 6, 2011Date of Patent: February 9, 2016Assignee: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Robert J. Hariri, Vladimir Jankovic, Aleksandr Kaplunovsky, Kristen Labazzo, Eric Law, Neerav D. Padliya, Jennifer Paredes, Jia-Lun Wang
-
Patent number: 9255248Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: GrantFiled: October 11, 2013Date of Patent: February 9, 2016Assignee: Anthrogenesis CorporationInventors: Stewart Abbot, Lin Kang, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Publication number: 20160030479Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.Type: ApplicationFiled: March 14, 2014Publication date: February 4, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, Tianjian Li, Bitao Liang
-
Publication number: 20160015749Abstract: Embodiments concern methods and/or compositions related to immunotherapy for cancer. In particular embodiments, engager immune cells harbor a vector that encodes a secretable engager molecule. In particular cases, the engager molecule has an activation domain and an antigen recognition domain. In some embodiments, the engager molecules further comprise a cytokine or co-stimulatory domain, for example.Type: ApplicationFiled: March 5, 2014Publication date: January 21, 2016Inventors: Stephen M. G. Gottschalk, Xiao-Tong Song, Kota Iwahori, Mireya Paulina Velasquez, Stewart Abbot
-
Publication number: 20160017282Abstract: Provided herein are placental stem cells that exhibit increased survival (“enhanced placental stem cells”), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.Type: ApplicationFiled: March 13, 2014Publication date: January 21, 2016Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, Kathy Karasiewicz-Mendez, Xiaokui Zhang
-
Publication number: 20150368360Abstract: Provided herein are modified T lymphocytes comprising chimeric receptors and methods of use thereof.Type: ApplicationFiled: February 6, 2014Publication date: December 24, 2015Applicant: ANTHROGENESIS CORPORATIONInventors: Bitao Liang, Stewart Abbot, Wei Liu
-
Publication number: 20150366910Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.Type: ApplicationFiled: February 4, 2014Publication date: December 24, 2015Inventors: Xiaokui ZHANG, Robert J. HARIRI, Vanessa VOSKINARIAN-BERSE, Lin KANG, Eric LAW, Stewart ABBOT
-
Patent number: 9198938Abstract: Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals.Type: GrantFiled: December 26, 2012Date of Patent: December 1, 2015Assignee: ANTRHOGENESIS CORPORATIONInventors: Stewart Abbot, James W. Edinger, Aleksandar Francki, Aleksandr Kaplunovsky, Vladimir Jankovic, Kristen Labazzo, Eric Law, Neerav Padliya, Jennifer Paredes, Jia-Lun Wang
-
Publication number: 20150307879Abstract: Anoikis resistant placental stem cells (arPSCs) with increased survival in low-attachment environments, and thus can advantageously be used, e.g., in therapies based on their ability to persist for longer durations of time in an unattached state. A method of modifying placental stem cells to make them anoikis resistant, comprising contacting the placental stem cells with an effective amount of modulatory RNA molecules, such that one or more genes associated with anoikis of the placental stem cells is inhibited. Further discloses are genes that are associated with anoikis for modulation.Type: ApplicationFiled: December 13, 2013Publication date: October 29, 2015Applicant: ANTHROGENESIS CORPORATIONInventors: Xiaokui Zhang, Stewart Abbot, Vanessa Voskinarian-Berse
-
Publication number: 20150307623Abstract: Provided herein are therapeutic polypeptides, e.g., chimeric antigen receptors, able to direct an immune cell, e.g., a T lymphocyte to a target antigen, and able to cause the T cell to proliferate or to kill cells displaying the antigen when the antigen binds to the polypeptide, wherein the polypeptides comprise a transmembrane domain from a T cell co-inhibitory protein such as CTLA4 or PD-1. Also provided herein are T lymphocytes expressing the polypeptides, and use of such T lymphocytes to treat diseases such as cancer.Type: ApplicationFiled: December 19, 2013Publication date: October 29, 2015Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, Bitao Liang, Tianjian Li
-
Publication number: 20150225697Abstract: Provided herein are methods of producing natural killer (NK) cells and NK progenitor cell populations using a two-step expansion and differentiation method. Also provided herein are methods of producing populations of NK cells and NK progenitor cell populations using a three-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells, the NK cell populations, and the NK progenitor cell populations produced by the methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: August 13, 2013Publication date: August 13, 2015Applicant: Anthrogenesis CorporationInventors: Eric Law, Lin Kang, Vladimir Jankovic, Xiaokui Zhang, Stewart Abbot, Robert J. Hariri
-
Publication number: 20150190434Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.Type: ApplicationFiled: January 16, 2015Publication date: July 9, 2015Applicant: ANTHROGENESIS CORPORATIONInventors: Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang
-
Publication number: 20150118265Abstract: Provided herein are modified erythrocyte precursor cells, erythrocytes generated from modified erythrocyte precursor cells, and uses thereof.Type: ApplicationFiled: March 12, 2013Publication date: April 30, 2015Applicant: Anthrogenesis CorporationInventors: James W. Edinger, Stewart Abbot, Bitao Liang
-
Patent number: 8969315Abstract: Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells.Type: GrantFiled: December 29, 2011Date of Patent: March 3, 2015Assignee: Anthrogenesis CorporationInventors: Stewart Abbot, Kathy E. Karasiewicz-Mendez, Vanessa Voskinarian-Berse, Xiaokui Zhang